TRCT
MGRX icon

Tower Research Capital (TRC)’s Mangoceuticals MGRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio MGRX Stock Details MGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$298 Sell
783
-2
-0.3% -$1 ﹤0.01% 5077
2026
Q1 		$283 Sell
785
-217
-22% -$104 ﹤0.01% 4925
2025
Q4 		$741 Buy
+1,002
New +$1.63K ﹤0.01% 4826
2025
Q3 		– Sell
-1,850
Closed -$2.81K – 5462
2025
Q2 		$2.81K Buy
1,850
+207
+13% +$388 ﹤0.01% 4591
2025
Q1 		$3.2K Sell
1,643
-990
-38% -$3.56K ﹤0.01% 4452
2024
Q4 		$6.37K Buy
+2,633
New +$6.9K ﹤0.01% 4180

Other funds holding MGRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
ACA
Ackerman Capital Advisors Dallas, Texas $497M AUM 16.31% 1-Year Est. Return
AA
ACT Advisors Asheville, North Carolina $301M AUM 23.36% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.47B AUM 24.93% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return
AG
AmeriFlex Group Las Vegas, Nevada $245M AUM 37.62% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

Tower Research Capital (TRC)'s MGRX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Mangoceuticals (MGRX) stake by 0.25% in Q2 2026, selling an estimated $1 and leaving 783 shares worth $298. The position accounts for ﹤0.01% of the portfolio, ranked #5077.

Tower Research Capital (TRC) first reported a position in MGRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $6.37K in Q4 2024. 12 funds tracked by Wall St. Rank hold MGRX as of Q2 2026.

  • Tower Research Capital (TRC) held 783 shares of Mangoceuticals worth $298 as of Q2 2026.
  • Tower Research Capital (TRC) sold 2 Mangoceuticals shares in Q2 2026, an estimated $1.
  • Mangoceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #5077 holding.
  • Tower Research Capital (TRC) first reported a position in Mangoceuticals in Q4 2024 and has held it in 6 quarters since.
  • Tower Research Capital (TRC)'s Mangoceuticals position peaked at $6.37K in Q4 2024.
  • 12 funds tracked by Wall St. Rank held Mangoceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.